Valuation : Grace Therapeutics, Inc.

Market Cap 64.79M 46.7M 40.24M 38.1M 34.53M 4.46B 65.11M 452M 174M 2.27B 175M 172M 7.17B P/E 2027 *
-1.85x
P/E 2028 * -4.81x
Enterprise Value 64.79M 46.7M 40.24M 38.1M 34.53M 4.46B 65.11M 452M 174M 2.27B 175M 172M 7.17B EV / Sales 2027 *
-
EV / Sales 2028 * 9.47x
Free-Float
81.8%
Yield 2027 *
-
Yield 2028 * -
1 day-1.77%
1 week+5.71%
Current month+4.23%
1 month+5.71%
3 months+0.91%
6 months-45.32%
Current year-35.84%
1 week 2.05
Extreme 2.05
2.46
1 month 2.02
Extreme 2.02
2.46
Current year 1.79
Extreme 1.79
5.18
1 year 1.79
Extreme 1.79
5.18
3 years 1.72
Extreme 1.72
5.18
5 years 1.72
Extreme 1.72
14.46
10 years 1.72
Extreme 1.72
161.11
Manager TitleAgeSince
Chief Executive Officer 54 04/04/2023
Director of Finance/CFO 55 05/01/2024
Chief Tech/Sci/R&D Officer 65 08/05/2023
Director TitleAgeSince
Director/Board Member 59 10/10/2023
Director/Board Member 57 10/10/2023
Director/Board Member 63 10/10/2023
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/26
Opaleye Management, Inc.
BuyCompany 5,836 0.0277%
9/9/26 Buy

Chief Executive Officer

100,000 0.4754%
28/8/26 Free

Executive/Senior Manager

35,760 0.1700%
Change 5-day change 1-year change 3-year change Capi.($)
-1.77%+5.71%-29.52%+9.90% 46.7M
-2.11%-1.68%+43.40%+95.27% 66.93B
-0.23%-4.45%+32.50%+75.75% 61.97B
+1.67%+2.47%-11.32%+380.54% 28.27B
-1.05%-4.43%+28.84%+10.59% 24.59B
+0.34%-6.78%-0.01%-16.35% 24.3B
+0.43%-3.37%+16.22%-17.99% 19.41B
-3.03%-2.29%+181.72%+335.27% 16.77B
-1.94%-4.94%-8.15%+483.69% 14.18B
+3.24%-0.31%-7.34%+880.45% 14.01B
Average -0.44%-2.08%+24.63%+223.71% 27.05B
Weighted average by Cap. -0.56%-2.82%+31.24%+170.66%

Financials

2027 *2028 *
Net sales - 6.84M 4.93M 4.25M 4.02M 3.65M 471M 6.88M 47.78M 18.37M 240M 18.52M 18.11M 757M
Net income -34.73M -25.03M -21.57M -20.42M -18.51M -2.39B -34.9M -243M -93.28M -1.22B -94.02M -91.96M -3.84B -16.92M -12.19M -10.51M -9.95M -9.02M -1.17B -17M -118M -45.44M -593M -45.8M -44.79M -1.87B
Net Debt - -
Logo Grace Therapeutics, Inc.
Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.
Employees
5
Date Price Change Volume
11/09/26 US$2.220 -1.77% 716,523
10/09/26 US$2.260 +5.61% 397,539
09/09/26 US$2.140 +0.94% 224,665
08/09/26 US$2.120 +0.95% 159,467
04/09/26 US$2.100 -1.87% 186,772
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.080CAD
Average target price
8.342CAD
Spread / Average Target
+170.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GRCE Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!